Tag: Psychedelic Medicine

The Nasdaq-listed psychedelic medicine developer will participate in four major healthcare conferences during November and December as it prepares for ...

Running from 2–8 November, the international event features online discussions, community gatherings and a keynote from Atai co-founder Christian Angermayer ...

The Australian psychedelic-assisted therapy provider has reported record quarterly revenue of $1.42 million, expanded its national clinic network and received ...

Published in JAMA, the phase 2b trial found that a single dose of the psychedelic compound 5-MeO-DMT significantly reduced depressive ...

Canadian pharmaceutical manufacturer Optimi Health has appointed experienced pharmaceutical executive Adrian Jones to lead its Australian operations, with a focus ...

The Nasdaq-listed psychedelic medicine developer is expanding its workforce, preparing a US sales operation and engaging healthcare providers ahead of ...

The Canadian pharmaceutical manufacturer says it is supplying 26 Australian clinics with naturally derived psilocybin and is targeting further growth ...

The Australian-founded biotechnology company is progressing three investigational treatments, including a synthetic psilocybin therapy for generalised anxiety disorder, as its ...

New Zealand medicinal cannabis company Rua Bioscience has signed a distribution agreement with PharmAla Biotech, following the country's first approvals ...

The three-day conference, hosted by entrepreneur Dave Asprey, brings together researchers, clinicians and business leaders to discuss psychedelic therapies, neuroscience ...